Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Telaglenastat (Primary)
- Indications Renal cell carcinoma
- Focus Proof of concept; Therapeutic Use
- Acronyms ENTRATA
- Sponsors Calithera Biosciences
- 16 May 2022 Results published in the Clinical Cancer Research
- 29 Jan 2021 Status changed from active, no longer recruiting to completed.
- 28 Sep 2019 Results presented in the Calithera Biosciences media release.